With a lens towards identifying key value, access, and pricing dynamics, our Cell and Gene Therapy Center of Excellence team can determine the influence these innovative treatments will have when entering the market.
Showing 5 of 11 posts
November 3, 2020 | Blog
New cell therapy technologies show blockbuster potential for improved accessibility and efficacy in a wide range of indications, though these therapies come with their own downfalls that healthcare systems will need to adapt to in order for these products to reach their full potential.
September 22, 2020 | Blog
CAR-Ts offer a significant clinical benefit for patients, however their full potential is currently limited by later line use at sites that are mostly academic centers, combined with significant logistical barriers. In CBPartners’ latest thought leadership article, our healthcare consultants look further into these barriers before assessing the opportunities that could bring CAR-Ts into earlier lines of treatment across oncology.
March 26, 2020 | Podcasts
In this episode, our host Jared Wolff is joined by healthcare consultants Sophie Katz (a core member of CBPartners' Cell and Gene Therapy Center of Excellence), and Jay Galli to discuss some interesting topics surrounding cell and gene therapies.
March 24, 2020 | Blog
A topic that is becoming increasingly popular in the healthcare space is Genome Editing. CBPartners’ Cell and Gene Therapy Center of Excellence team explores the development of these technologies as they present an immense opportunity for the future of the pharmaceutical industry.
November 10, 2019 | Blog, News
The American Society of Hematology’s (ASH) annual meeting is a well-established indicator of the innovations that are coming down the pipeline for hematologic diseases. CBPartners’ Cell and Gene Therapy Center of Excellence explored eight promising presentations from the CAR T event.